Sangamo Therapeutics has announced it has entered into an agreement with TxCell to acquire a majority stake in the regulatory T cell developer. With this acquisition, Sangamo aims to combine its ex vivo gene editing portfolio with TxCell’s Treg expertise to establish the company as a leader in CAR-Treg development.
Sangamo will acquire a majority stake of TxCell for approximately $84 million on a debt-free and cash-free basis. The transaction is expected to be complete in the fourth quarter of 2018.
TxCell is a developer of platforms for personalized T cell immunotherapies in the treatment of severe inflammatory and autoimmune diseases, and a leader in the emerging regulatory T cell field. Sangamo aim to assess the potential of CAR-Treg therapies for the prevention of graft rejection in solid organ transplant and in the treatment of autoimmune diseases such as multiple sclerosis and Crohn’s. Data from preclinical research of CAR-Tregs has provided proof of concept that antigen specific CAR-Tregs are able to deliver potent immunosuppression locally to targeted tissues.
Following this acquisition, Sangamo hopes to accelerate development and entry into the clinic with a CAR-Treg therapy. They expect to submit a clinical trial authorization application in Europe for TxCell’s first CAR-Treg investigational product candidate for solid organ transplant in 2019, and initiate a Phase I/II clinical trial later in the year. Furthermore, Sangamo plan to begin development of next generation autologous and allogeneic CAR-Treg therapies using its zinc finger nuclease (ZFN) gene editing technology.
“We are excited to combine with Sangamo for their experience and technical expertise in gene-edited cell therapy, and we believe Sangamo’s ZFN editing technology will facilitate the precise genetic modifications needed to create a new class of Treg-based antigen and tissue specific immunosuppressive medicines,” said Stephane Boissel, CEO of TxCell.
Source: Sangamo Therapeutics to Acquire TxCell Press Release